[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100520265":3},{"organization":4,"armGroups":7,"interventions":28,"overallOfficials":45,"centralContacts":49,"locations":59,"responsibleParty":78,"collaborators":53,"id":81,"slug":82,"hasResults":83,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":83,"sex":89,"minAge":90,"maxAge":91,"enrollmentInfo":92,"targetDuration":53,"studyType":95,"phases":96,"briefSummary":98,"conditions":99,"keywords":101,"overallStatus":61,"whyStopped":53,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":115},{"fullName":5,"class":6},"Chonnam National University Hospital","OTHER",[8,14,20,24],{"label":9,"type":10,"description":11,"interventionNames":12},"Good responder group-stepwise pharmacotherapy group","EXPERIMENTAL","Using multimodal serum biomarker scores, patients will be divided into good\u002Fpoor responder. Then good responder group will be randomized into stepwise pharmacotherapy group vs antidepressant monotherapy(escitalopram) group.\n\nIn the stepwise pharmacotherapy group, treatment strategies (augmentation with antipsychotics (aripiprazole), augmentation with mood stabilizer (lithium),combination (mirtazapine)) will be determined every 3 weeks.",[13],"Drug: stepwise pharmacotherapy",{"label":15,"type":16,"description":17,"interventionNames":18},"Good responder group-antidepressant monotherapy group","ACTIVE_COMPARATOR","Using multimodal serum biomarker scores, patients will be divided into good\u002Fpoor responder. Then good responder group will be randomized into stepwise pharmacotherapy group vs antidepressant monotherapy(escitalopram) group.\n\nIn the antidepressant monotherapy group, dosage escalation will be determined every 3 weeks.",[19],"Drug: antidepressant monotherapy group",{"label":21,"type":10,"description":22,"interventionNames":23},"Poor responder group-stepwise pharmacotherapy group","Using multimodal serum biomarker scores, patients will be divided into good\u002Fpoor responder. Then poor responder group will be randomized into stepwise pharmacotherapy group vs antidepressant monotherapy(escitalopram) group.\n\nIn the stepwise pharmacotherapy group, treatment strategies (augmentation with antipsychotics (aripiprazole), augmentation with mood stabilizer (lithium),combination (mirtazapine)) will be determined every 3 weeks.",[13],{"label":25,"type":16,"description":26,"interventionNames":27},"Poor responder group-antidepressant monotherapy group","Using multimodal serum biomarker scores, patients will be divided into good\u002Fpoor responder. Then poor responder group will be randomized into stepwise pharmacotherapy group vs antidepressant monotherapy(escitalopram) group.\n\nIn the antidepressant monotherapy group, dosage escalation will be determined every 3 weeks.",[19],[29,39],{"type":30,"name":31,"description":32,"armGroupLabels":33,"otherNames":34},"DRUG","stepwise pharmacotherapy","In the stepwise pharmacotherapy group, treatment strategies (augmentation with antipsychotics (aripiprazole), augmentation with mood stabilizer (lithium),combination (mirtazapine)) will be determined every 3 weeks.",[9,21],[35,36,37,38],"escitalopram","escitalopram with aripiprazole augmentation","escitalopram with lithium augmentation","escitalopram with mirtazapine combination",{"type":30,"name":40,"description":41,"armGroupLabels":42,"otherNames":43},"antidepressant monotherapy group","In the antidepressant monotherapy group, dosage escalation will be determined every 3 weeks.",[15,25],[44],"escitalopram monotherapy",[46],{"name":47,"affiliation":5,"role":48},"Jae-Min Kim, MD, PhD","PRINCIPAL_INVESTIGATOR",[50,55],{"name":47,"role":51,"phone":52,"phoneExt":53,"email":54},"CONTACT","82-62-220-6043",null,"jmkim@chonnam.ac.kr",{"name":56,"role":51,"phone":57,"phoneExt":53,"email":58},"Hee-Ju Kang, MD, PhD","82-62-220-5961","hjkang82@chonnam.ac.kr",[60],{"facility":5,"status":61,"city":62,"state":53,"zip":63,"country":64,"countryCode":53,"cosmosGeoPoint":65,"geoPoint":70,"contacts":71},"RECRUITING","Gwangju","61469","South Korea",{"type":66,"coordinates":67},"Point",[68,69],126.91556,35.15472,{"lat":69,"lon":68},[72,76],{"name":73,"role":51,"phone":74,"phoneExt":53,"email":75},"Young-Gwang Lee, CRC","82-62-220-6152","gloryworld@nate.com",{"name":77,"role":48,"phone":53,"phoneExt":53,"email":53},"Jae-Min Kim, Md, PhD",{"type":48,"investigatorFullName":79,"investigatorTitle":80,"investigatorAffiliation":5,"oldNameTitle":53,"oldOrganization":53},"Jae-Min Kim","Professor","100520265","psychopharmacotherapy-for-depressive-patients-100520265",false,"NCT06054321","Psychopharmacotherapy for Depressive Patients","A Randomized Clinical Trial of Response to Psychopharmacotherapy According to Multimodal Serum Biomarkers in Depressive Patients","BMDD-2022","Inclusion Criteria:\n\n* 19 to 65 years\n* Diagnostic and Statistical Manual of Mental Disorders-IV criteria for major depressive disorder by study psychiatrists\n* Score≥17 on Hamilton Depression Rating Scale-17\n* With ability to understand the objective of the study and sign informed consent\n* Initiation of an antidepressant treatment for the current episode or no psychotropics excluding sleep pills or benzodiazepines within 1 month of participation\n\nExclusion Criteria:\n\n* Current or lifetime diagnosis of bipolar disorder, schizophrenia, schizoaffective disorder, schizophreniform disorder, psychotic disorder not otherwise specified, or other psychotic disorders\n* current major depressive disorder with psychotic features\n* History of organic psychosis, epilepsy, or seizure disorder\n* Current anorexia nervosa or obsessive compulsive disorder\n* Unstable or uncontrolled medical condition\n* Unable to complete the psychiatric assessment or comply with the medication regimen due to a severe physical illness\n* History of anticonvulsant treatment\n* Electroconvulsive therapy for the current depressive episode\n* Hospitalization for any psychiatric diagnosis except depressive disorder (e.g., alcohol\u002Fdrug dependence)\n* severly high risk of suicide, self-harm or homicide by investigator's assessment\n* Pregnant or breastfeeding\n* lack of treatment information on the current depressive episode","ALL","19 Years","65 Years",{"count":93,"type":94},400,"ESTIMATED","INTERVENTIONAL",[97],"NA","The primary purpose of this study is to compare the short (12 week) and long-term (1-year) efficacy and the tolerability between stepwise psychopharmacotherapy and antidepressant monotherapy for 12 weeks in adult patients with major depressive disorders, stratified by the multimodal serum biomarker scores.",[100],"Major Depressive Disorder",[102,103,104,105],"depression","antidepressant monotherapy","stepwise psychopharmacotherapy","multimodal serum biomarker score","2024-04-16",{"date":108,"type":109},"2024-04-18","ACTUAL",{"date":111,"type":109},"2022-08-03",{"date":113,"type":94},"2030-12-31",{"name":5,"class":6},1]